Growth Hormone Decline: The Age-Related Pattern
Human growth hormone (HGH) is secreted by the anterior pituitary in pulsatile bursts, primarily during deep sleep and in response to exercise and fasting. Peak GH secretion occurs in adolescence; after age 30, GH output declines approximately 14% per decade. This decline — termed somatopause — is associated with increased body fat (particularly visceral), decreased lean mass, reduced bone density, impaired sleep quality, and decreased exercise capacity.
Diagnosis of Adult Growth Hormone Deficiency (AGHD)
True adult GHD requires stimulation testing (insulin tolerance test or glucagon stimulation test) for definitive diagnosis and is distinct from the age-related decline most optimization patients experience. IGF-1 (insulin-like growth factor-1) is the clinical proxy for GH status — it is produced by the liver in response to GH and reflects average GH secretion over 24 hours. IGF-1 below the lower third of age-adjusted reference range with clinical symptoms warrants further evaluation.
Exogenous HGH: Clinical Use and Limitations
Pharmaceutical-grade HGH (somatropin) is FDA-approved for AGHD, HIV-related wasting, and short stature. Off-label use for anti-aging and optimization is widespread but regulatory. HGH is expensive ($500–$2,000+/month), requires daily or twice-daily subcutaneous injection, carries risks of edema, joint pain, carpal tunnel, glucose intolerance, and theoretical cancer promotion concerns, and is a Schedule III controlled substance. Its use should be reserved for documented deficiency with compelling clinical indication.
Growth Hormone Secretagogues: The Preferred Alternative
For most optimization patients, growth hormone secretagogues (GHS) offer a safer, more physiologic, and more cost-effective approach than exogenous HGH. GHS stimulate the pituitary to release growth hormone naturally, preserving pulsatile secretion patterns. Key peptide GHS include: Sermorelin (GHRH analog), CJC-1295 with Ipamorelin (GHRH analog + ghrelin mimetic combination), and Tesamorelin (FDA-approved for HIV lipodystrophy). These are prescribed via compounding pharmacy for optimization use.
Clinical Protocol Considerations
Standard GHS protocols involve nightly subcutaneous injection (taken before bed, during the period of maximal natural GH release). Baseline IGF-1 before initiation and monitoring at 6–8 weeks guides dose titration. Target IGF-1 in the upper-normal range for age. Cycles of 3–6 months on, 1–2 months off are common clinical practice, though evidence for cycling is largely empirical.
Educating Patients on Realistic Outcomes
Set realistic expectations. GHS therapy typically produces gradual improvements over 3–6 months: improved sleep quality (often the first benefit noticed), modest body composition improvements (not dramatic), faster recovery, and often improved skin quality. It is not a substitute for training, nutrition, and foundational hormone optimization. Patients who expect dramatic body transformation will be disappointed — those who seek comprehensive optimization often value it highly.